Literature DB >> 6470925

Nuclear binding as a determinant of tissue distribution of adriamycin, daunomycin, adriamycinol, daunorubicinol and actinomycin D.

T Terasaki, T Iga, Y Sugiyama, Y Sawada, M Hanano.   

Abstract

The tissue distribution mechanism of adriamycin (ADR), its relatives, daunomycin (DNR), adriamycinol (ADR-ol), daunorubicinol (DNR-ol) and actinomycin D (ACT-D) has been studied in rats and rabbits. The following evidences with respect to tissue distribution of ADR were obtained: 1) remarkable binding of ADR to tissue homogenate, 2) significant difference in the tissue binding of ADR among tissues, 3) exclusive localization of ADR in cell nucleus, 4) good correlation between the tissue binding of ADR and the tissue desoxyribonucleic acid (DNA) concentration, 5) comparatively good coincidence between the experimentally determined tissue binding of ADR and that calculated from in vitro nuclear binding parameters reported and the tissue DNA concentration, and 6) no correlation between the concentration of tissue phospholipids (i.e. cardiolipin, acidic phospholipids and total phospholipids) and the Kp value of ADR in rats. From these findings, it was confirmed that the nuclear binding is a determinant of the extensive tissue distribution of ADR and that a remarkable variation in the tissue concentration of ADR is due mainly to the difference in the tissue DNA concentration. Furthermore, good correlations were demonstrated between the DNA concentration and Kpapp values of DNR and ACT-D in rats and DNR, ADR-ol and DNR-ol in rabbits. Hence, it is suggested that there is a common mechanism of in vivo tissue distribution of ADR and its relatives which can intercalate to DNA and the determinant of characteristic tissue distribution is nuclear binding of these antibiotics.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6470925     DOI: 10.1248/bpb1978.7.269

Source DB:  PubMed          Journal:  J Pharmacobiodyn        ISSN: 0386-846X


  8 in total

1.  Treatment of Invasive Brain Tumors Using a Chain-like Nanoparticle.

Authors:  Pubudu M Peiris; Aaron Abramowski; James Mcginnity; Elizabeth Doolittle; Randall Toy; Ramamurthy Gopalakrishnan; Shruti Shah; Lisa Bauer; Ketan B Ghaghada; Christopher Hoimes; Susann M Brady-Kalnay; James P Basilion; Mark A Griswold; Efstathios Karathanasis
Journal:  Cancer Res       Date:  2015-01-27       Impact factor: 12.701

2.  Enhanced delivery of chemotherapy to tumors using a multicomponent nanochain with radio-frequency-tunable drug release.

Authors:  Pubudu M Peiris; Lisa Bauer; Randall Toy; Emily Tran; Jenna Pansky; Elizabeth Doolittle; Erik Schmidt; Elliott Hayden; Aaron Mayer; Ruth A Keri; Mark A Griswold; Efstathios Karathanasis
Journal:  ACS Nano       Date:  2012-04-13       Impact factor: 15.881

3.  Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit.

Authors:  B J Cusack; S P Young; J Driskell; R D Olson
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 4.  Crossing the barrier: treatment of brain tumors using nanochain particles.

Authors:  Efstathios Karathanasis; Ketan B Ghaghada
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-01-09

5.  Doxorubicin binds in a cooperative manner to myocardial cells. Two binding sites.

Authors:  K Wassermann; E Steiness
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

6.  Treatment of cancer micrometastasis using a multicomponent chain-like nanoparticle.

Authors:  Pubudu M Peiris; Randall Toy; Aaron Abramowski; Pete Vicente; Samantha Tucci; Lisa Bauer; Aaron Mayer; Morgan Tam; Elizabeth Doolittle; Jenna Pansky; Emily Tran; Dishen Lin; William P Schiemann; Ketan B Ghaghada; Mark A Griswold; Efstathios Karathanasis
Journal:  J Control Release       Date:  2013-11-02       Impact factor: 9.776

7.  Interaction of anthraquinones of Cassia occidentalis seeds with DNA and Glutathione.

Authors:  Gati Krushna Panigrahi; Neeraj Verma; Nivedita Singh; Somya Asthana; Shailendra K Gupta; Anurag Tripathi; Mukul Das
Journal:  Toxicol Rep       Date:  2018-01-03

8.  Detection of Adriamycin-DNA adducts by accelerator mass spectrometry at clinically relevant Adriamycin concentrations.

Authors:  Kate E Coldwell; Suzanne M Cutts; Ted J Ognibene; Paul T Henderson; Don R Phillips
Journal:  Nucleic Acids Res       Date:  2008-07-16       Impact factor: 16.971

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.